Argos Therapeutics Reports Results of Interim Analysis of the ADAPT Trial and Announces Review of Strategic Alternatives
19 avr. 2018 08h00 HE
|
Argos Therapeutics, Inc.
- Company to terminate the ADAPT study – - Company has retained Stifel to provide advice on possible strategic alternatives – - Trading in the common stock to be transferred from Nasdaq to the OTCQB...
Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights
02 avr. 2018 08h30 HE
|
Argos Therapeutics, Inc.
DURHAM, NC, April 02, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Therapeutics to Report Fourth Quarter and Year-End 2017 Financial Results and Operational Highlights on Monday, April 2, 2018
28 mars 2018 17h00 HE
|
Argos Therapeutics, Inc.
DURHAM, N.C., March 28, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy
15 févr. 2018 08h30 HE
|
Argos Therapeutics, Inc.
DURHAM, N.C., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Obtains Option to License PD1 Checkpoint Inhibitors
05 févr. 2018 16h47 HE
|
Argos Therapeutics, Inc.
- Data showing synergy between PD1 checkpoint inhibition and analogue of Rocapuldencel-T in a preclinical model of renal carcinoma presented at ASCO-SITC - - Company to host a conference call on...
Argos Announces One-for-Twenty Reverse Stock Split
18 janv. 2018 08h00 HE
|
Argos Therapeutics, Inc.
DURHAM, N.C., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Announces $1.5 Million Equity Investment by Lummy (Hong Kong), Ltd.
08 janv. 2018 08h30 HE
|
Argos Therapeutics, Inc.
DURHAM, N.C., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Provides Financial Update
28 nov. 2017 08h00 HE
|
Argos Therapeutics, Inc.
DURHAM, N.C., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting
11 nov. 2017 08h30 HE
|
Argos Therapeutics, Inc.
DURHAM, N.C., Nov. 11, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Reports Third Quarter 2017 Financial Results and Operational Highlights
09 nov. 2017 16h46 HE
|
Argos Therapeutics, Inc.
DURHAM, N.C., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...